Endocrine Abstracts

ACROSTUDY is an international observational study to evaluate efficacy and safety of long-term treatment with pegvisomant (PEGA) in acromegaly. ACROSTUDY Italy was started in 2007 and we report data from the first 185 patients (93M, 92F, mean age, range, 49.9 y; 17–83.8 y) treated with PEGA (mean duration, range, 3.2 y, 0.1–8.5 y), from 24 centers, until 01/2010. Before and during PEGA, IGF1, GH-Ab, liver enzymes, metabolic parameters and pituitary MRI were assessed....

Introduction: Acromegaly is characterized by high cardiovascular morbidity and mortality possibly due to increased prevalence of main traditional cardiovascular risk factors. It is not clear though whether the incidence of atherosclerosis is truly enhanced. Moreover recent in vitro studies show a protective role of (GH) and IGF1 (insulin-like growth factor-1) on the endothelium. As expression of endothelial regenerative reserve, endothelial progenitor cells (EPCs) could...

GH hypersection results in biventricular concentric hypertrophy and a progressive contractile impairment whereas cardiac hypotrophy and impaired diastolic filling and left ventricular function have been reported in GH deficiency (GHD). No information on cardiac performances and structure are available about those acromegalic patients in whom successful treatment made their GH and IGF-I secretion similar to those in GHD patients. In order to study the functional and structural ...